ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Wei Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9616-1145; OpenAlex author ID A5054667546. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper

Papers 2

A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2025.102364 ↗
Combining prognostic value of serum carbohydrate antigen 19-9 and tumor size reduction ratio in pancreatic ductal adenocarcinoma. Last author DOI 10.4251/wjgo.v16.i3.798 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Dong-Qin Xia · 1 shared paper, 2024 · strength 0.22
- Paper Combining prognostic value of serum carbohydrate antigen 19-9 and tumor size reduction ratio in pancreatic ductal adeno… DOI 10.4251/wjgo.v16.i3.798 ↗
Miaoyan Wei · 1 shared paper, 2025 · strength 0.20
- Paper A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metasta… DOI 10.1016/j.xcrm.2025.102364 ↗
Chen Liu · 1 shared paper, 2025 · strength 0.20
- Paper A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metasta… DOI 10.1016/j.xcrm.2025.102364 ↗
Xianjun Yu · 1 shared paper, 2025 · strength 0.20
- Paper A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metasta… DOI 10.1016/j.xcrm.2025.102364 ↗
Xiaowu Xu · 1 shared paper, 2025 · strength 0.20
- Paper A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metasta… DOI 10.1016/j.xcrm.2025.102364 ↗
Jin Xu · 1 shared paper, 2025 · strength 0.20
- Paper A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metasta… DOI 10.1016/j.xcrm.2025.102364 ↗
Si Shi · 1 shared paper, 2025 · strength 0.20
- Paper A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metasta… DOI 10.1016/j.xcrm.2025.102364 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.